Natera co-founder Sheena Jonathan sells 4,650 shares
Natera, Inc. co-founder and director Sheena Jonathan reported 13 sales totaling 4,650 shares of Natera common stock on May 8 and May 13, 2026, at weighted-average prices between $199.00 and $210.3450 per share, effected under Rule 10b5-1 trading plans.
Rhea-AI Filing Summary
Natera, Inc. co-founder and director Sheena Jonathan reported 13 sales totaling 4,650 shares of Natera common stock on May 8 and May 13, 2026, at weighted-average prices between $199.00 and $210.3450 per share, effected under Rule 10b5-1 trading plans. After these trades, she holds 252,502 shares directly, with 19,532 shares held by Caraluna 1 Trust and 19,532 shares by Caraluna 2 Trust; the trust shares are held for beneficiaries, and Jonathan disclaims beneficial ownership of those securities.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 85 | $199.5174 | $17K |
| Sale | Common Stock | 345 | $201.1139 | $69K |
| Sale | Common Stock | 290 | $202.5823 | $59K |
| Sale | Common Stock | 30 | $202.84 | $6K |
| Sale | Common Stock | 96 | $199.4346 | $19K |
| Sale | Common Stock | 360 | $201.1923 | $72K |
| Sale | Common Stock | 285 | $202.6829 | $58K |
| Sale | Common Stock | 9 | $203.295 | $2K |
| Sale | Common Stock | 200 | $205.43 | $41K |
| Sale | Common Stock | 900 | $207.2411 | $187K |
| Sale | Common Stock | 700 | $208.1286 | $146K |
| Sale | Common Stock | 200 | $209.5725 | $42K |
| Sale | Common Stock | 1,150 | $210.345 | $242K |
Footnotes (14)
- F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.86 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.52 to $207.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.55 to $208.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.2250 to $209.9200 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
- F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.00 to $199.8950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
- F9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.81 to $201.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.83 to $202.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.83 to $202.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.00 to $199.8950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F13. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.81 to $201.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F14. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.9750 to $202.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
beneficial ownership regulatory
indirect ownership financial
open market or private transaction financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did NTRA co-founder Sheena Jonathan report in this Form 4?
Were the NTRA insider sales by Sheena Jonathan made under Rule 10b5-1 trading plans?
What is the role of the Caraluna trusts in Sheena Jonathan’s NTRA holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.